The reduction in the price target for NeoGenomics by BTIG suggests that there may be factors that could limit the stock's upside potential in the short term. However, maintaining a Buy rating indicates that the overall outlook remains positive. This could lead to a neutral short-term impact on the stock price as the market digests the mixed signals of a lower price target with a maintained Buy rating.